Also categorized in Global Health:
Targeting the Type I Interferon Pathway to Treat Patients With Lupus
x hide permanently

NIH Launches Study of Extra COVID-19 Vaccine Dose in People with Autoimmune Disease

EurekAlert! Science News Releases

Photo: NIAID

EurekAlert.org

The National Institutes of Health has begun a clinical trial to assess the antibody response to an extra dose of an authorized or approved COVID-19 vaccine in people with autoimmune disease who did not respond to an original COVID-19 vaccine regimen. The trial also will investigate whether pausing immunosuppressive therapy for autoimmune disease improves the antibody response to an extra dose of a COVID-19 vaccine in this population. The Phase 2 trial is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, and is being conducted by the NIAID-funded ...